Debora brauser
February 4 2020
The US Food and Drug Administration (FDA) has granted a new marketing clearance for the ActiPatch (BioElectronics Corp) — an over-the-counter electromagnetic neuromodulation device for treating pain, the manufacturer has announced.
The new 510(k) clearance is indicated for adjunctive treatment of any musculoskeletal pain. This joins previous FDA clearance granted for the noninvasive device in 2017 to treat knee osteoarthritis and plantar fasciitis.
Read more: https://www.medscape.com/viewarticle/924762